Half-year report · Q2

Period2024-01-01 → 2024-06-30
Filed2024-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥316m2024-01-01 → 2024-06-30Cons.Net sales
Revenue¥1.6bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥501m2023-01-01 → 2023-06-30Cons.Net sales
Operating income−¥1.1bn2024-01-01 → 2024-06-30Cons.Operating income
Operating income−¥864m2023-01-01 → 2023-06-30Cons.Operating income
Ordinary income−¥1.1bn2024-01-01 → 2024-06-30Cons.Ordinary income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥868m2023-01-01 → 2023-06-30Cons.Ordinary income
Profit before tax−¥1.1bn2024-01-01 → 2024-06-30Cons.Income before income taxes
Profit before tax−¥869m2023-01-01 → 2023-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.2bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥886m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss
Net income−¥886m2023-01-01 → 2023-06-30Cons.Profit loss
Total assets¥3.7bnat 2024-06-30Cons.Assets
Total assets¥4.3bnat 2023-12-31Cons.Assets
Total assets¥4.6bnat 2023-06-30Cons.Total assets (5-year summary)
Total liabilities¥470mat 2024-06-30Cons.Liabilities
Total liabilities¥472mat 2023-12-31Cons.Liabilities
Net assets / equity¥3.2bnat 2024-06-30Cons.Net assets
Net assets / equity¥3.9bnat 2023-12-31Cons.Net assets
Net assets / equity¥4.1bnat 2023-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.0bnat 2024-06-30Cons.Cash and deposits
Cash and deposits¥2.9bnat 2023-12-31Cons.Cash and deposits
Cash & equivalents¥3.0bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31dCons.Cash and cash equivalents
Operating cash flow−¥222m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.7bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥939m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥11m2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥279m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.2bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-63.252024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-68.622023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-53.812023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio87.2%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.1%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.9%at 2023-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥1.1bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥24m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥169m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 417
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任監査法人トーマツ
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)西  方     実
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)安 場 達 哉
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration500570000JPY
Net sales (5-year summary)CurrentYTDDuration315642000JPY
Net sales (5-year summary)Prior1YearDuration1625889000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration-868405000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration-1087156000JPY
Ordinary income loss (5-year summary)Prior1YearDuration-1126283000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration-885608000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration-1094118000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration-1152895000JPY
Comprehensive income (5-year summary)Prior1YTDDuration-861390000JPY
Comprehensive income (5-year summary)CurrentYTDDuration-1026469000JPY
Comprehensive income (5-year summary)Prior1YearDuration-1135377000JPY
Net assets (5-year summary)Prior1QuarterInstant4111801000JPY
Net assets (5-year summary)CurrentQuarterInstant3215316000JPY
Net assets (5-year summary)Prior1YearInstant3877535000JPY
Total assets (5-year summary)Prior1QuarterInstant4565118000JPY
Total assets (5-year summary)CurrentQuarterInstant3685650000JPY
Total assets (5-year summary)Prior1YearInstant4349891000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration-53.81
Basic earnings loss per share (5-year summary)CurrentYTDDuration-63.25
Basic earnings loss per share (5-year summary)Prior1YearDuration-68.62
Diluted earnings per share (5-year summary)Prior1YTDDuration-
Diluted earnings per share (5-year summary)CurrentYTDDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.899
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.872
Equity to asset ratio (5-year summary)Prior1YearInstant0.891
Net cash provided by used in operating activities (5-year summary)Prior1YTDDuration-938544000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYTDDuration-222059000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration-1677464000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YTDDuration-6854000JPY
Net cash provided by used in investing activities (5-year summary)CurrentYTDDuration-7108000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration-11376000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YTDDuration1222158000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYTDDuration279068000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration1182027000JPY
Cash and cash equivalents (5-year summary)Prior1QuarterInstant3684625000JPY
Cash and cash equivalents (5-year summary)CurrentQuarterInstant3026030000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant2889101000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember18056900
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember18056900
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant18056900
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant18056900
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember841112
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.0466

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass